What was recalled
The U.S. Food and Drug Administration (FDA) has issued a Class II recall involving a specific prescription medication manufactured by Cipla USA, Inc. This action targets Cinacalcet Hydrochloride Tablets in the 90 mg strength, packaged in 30-count bottles. The product is marked with the brand name "Cipla" and carries the National Drug Code (NDC) number 69097-412-02. It is important to note that this is a prescription-only medication, meaning it is not available over-the-counter and must be dispensed by a licensed pharmacy under a doctor’s order.
The tablets in question were manufactured by Cipla Ltd., located in MIDC, Patalganga, India, on behalf of Cipla USA, Inc. The company’s address is listed as 10 Independence Boulevard, Suite 300, Warren, NJ 07059. The specific lot affected by this recall is identified as Lot #5PB0563, with an expiration date of April 30, 2027. This means the product was still within its stated shelf life at the time of the recall announcement.
The recall was initiated on June 29, 2026. The affected products were distributed nationwide across the United States, including the state of New Jersey. Because the distribution pattern is nationwide, individuals in any state could potentially possess this recalled item if they filled a prescription during the relevant time frame.
Cinacalcet Hydrochloride is typically prescribed to treat high parathyroid hormone levels and high calcium levels in people with certain medical conditions, such as hyperparathyroidism associated with parathyroid gland cancer or secondary hyperparathyroidism in adults with chronic kidney disease on dialysis. The specific bottle size of 30 counts is a common dispensing quantity for monthly prescriptions.
If you have recently filled a prescription for Cinacalcet Hydrochloride 90 mg tablets, it is crucial to check your medication bottle against the details provided above. Look specifically for the NDC number 69097-412-02 and the lot number 5PB0563. If these match, you are in possession of the recalled product. The recall affects only this specific lot; other lots with different numbers may be safe and unaffected.
It is important to remember that this is a Class II recall. In FDA terminology, a Class II classification indicates that use or exposure to the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This means while the issue needs to be addressed promptly, it is not necessarily an immediate life-threatening emergency for every individual.
If you are unsure whether your medication is part of this recall, contact your pharmacy first. They can look up the lot number on their records and confirm if it matches the recalled batch. You can also reach out to Cipla USA, Inc. directly for more information. Their contact details should be available on their website or through your healthcare provider.
Please do not stop taking your medication abruptly without consulting your doctor. Suddenly stopping Cinacalcet Hydrochloride could lead to a dangerous rise in your calcium levels. Your healthcare provider can advise you on how to safely transition to a non-recalled supply of the same medication or an alternative treatment if necessary.
The recall was announced by the FDA to ensure public safety and maintain trust in the pharmaceutical supply chain. By identifying and removing potentially compromised products from the market, regulatory agencies work to prevent any adverse effects that could arise from manufacturing deviations. This proactive step is a standard part of the FDA’s oversight responsibilities.
If you have questions about the health implications of taking this medication, or if you experience any unusual symptoms, contact your healthcare provider immediately. They can provide personalized medical advice based on your specific health history and current condition. Always prioritize your safety and well-being when dealing with prescription medications.
The hazard, explained
When we talk about a Class II recall involving pharmaceutical manufacturing, it is helpful to understand that this classification indicates a situation that might cause temporary health problems or pose slight threat of serious nature, but is not expected to cause serious adverse health consequences. In the specific case of the Cipla USA, Inc. recall regarding their Cinacalcet Hydrochloride Tablets, the core issue stems from what is known as current Good Manufacturing Practice (cGMP) deviations. These are procedural or environmental failures during the production process that compromise the strict standards required to ensure a drug’s safety and purity.
The specific technical failure here involves the presence of N-nitroso-cinacalcet, an impurity found in the medication above the acceptable daily intake (ADI) level. To understand why this matters, we must look at what N-nitroso compounds are. These are a class of chemicals that can form under certain conditions when nitrogen-containing compounds react with nitrites or nitrates. In the context of pharmaceuticals, their presence is typically flagged because many N-nitroso compounds are recognized as potential carcinogens—meaning they have the potential to cause cancer—with risk levels generally assessed based on how much of the substance a person consumes over time.
The "acceptable daily intake" is a regulatory threshold established by safety experts. It represents the amount of a substance that can be ingested every day for a lifetime without posing a significant risk to health. When a drug contains an impurity above this limit, it means the exposure level exceeds what authorities have deemed safe. While one might wonder how this happens, cGMP deviations often relate to subtle issues in raw material sourcing, storage conditions, or chemical stability during manufacturing. Even if the primary ingredient, Cinacalcet Hydrochloride, is intended to work correctly for its medical purpose—typically managing parathyroid hormone levels—the presence of excessive impurities introduces an unknown variable into the patient’s body.
It is important to clarify that the presence of this impurity does not necessarily mean the drug will fail to treat the condition it was prescribed for, nor does it mean immediate harm will occur from a single dose. However, the risk is cumulative. For patients who take this medication daily over months or years, the elevated levels of N-nitroso-cinacalcet contribute to a higher overall exposure than intended. Regulatory agencies like the FDA classify such recalls as Class II because while the immediate danger may not be acute toxicity (like poisoning), the long-term health implications of exceeding safe limits for potential carcinogens are taken very seriously. This is why the recall is necessary: to remove products where the manufacturing process failed to keep impurity levels within the strictly defined safety boundaries.
Furthermore, cGMP deviations suggest that the manufacturing environment or protocol did not adhere to the rigorous quality controls designed to prevent such contaminants from forming or persisting in the final product. This is not merely a paperwork error; it is a physical failure in the production chain that results in a product that does not meet its own purity specifications. For consumers, understanding this mechanism highlights why recalls are proactive measures. They are designed to catch these subtle chemical imbalances before they can affect public health on a broader scale, ensuring that the medication you take is both effective and chemically pure.
Who is most at risk
To understand who faces the greatest concern in this recall, we first need to look at the nature of the medication itself. Cinacalcet hydrochloride is not a general over-the-counter supplement; it is a prescription drug used primarily to manage parathyroid hormone levels in adults with hyperparathyroidism or secondary hyperparathyroidism associated with chronic kidney disease. This means that anyone currently taking this specific 90 mg tablet from Cipla USA, Inc., specifically those with lot number 5PB0563 and an expiration date of April 30, 2027, is the primary group affected by this issue. These individuals are relying on this medication to maintain a delicate chemical balance in their bodies, making any deviation in drug quality particularly significant for their ongoing health management.
The specific hazard here involves cGMP deviations, namely the presence of N-nitroso-cinacalcet above the acceptable daily intake level. While the FDA has not reported any immediate adverse events or injuries linked to this specific batch as of the recall date on June 29, 2026, the potential for harm is rooted in what nitrosamines are. These compounds are generally recognized by medical experts as potential carcinogens, meaning substances that may cause cancer with long-term exposure. For a patient taking this medication daily to manage a chronic condition, even small amounts of an unwanted impurity can accumulate over time. This creates a unique risk profile that differs from acute poisoning or immediate allergic reactions; the concern is largely about long-term safety and the integrity of the treatment plan.
While any patient on this drug should take this recall seriously, certain groups may be more vulnerable to the implications of this issue. Patients with pre-existing kidney issues often have reduced ability to filter toxins from their blood, which can make them more sensitive to impurities in their medications. Additionally, older adults who are already managing multiple health conditions and taking several different prescriptions face a higher burden of potential drug interactions or compounded side effects if they were to experience unexpected reactions. Because Cinacalcet affects calcium levels in the body, patients with complex metabolic disorders must be especially vigilant about maintaining their prescribed dosage without interruption, as sudden changes or substitutions can destabilize their condition.
It is also important to note that this recall is classified as a Class II recall by the FDA. In medical terms, this classification indicates that use of the product might cause temporary health problems or pose a slight threat of a serious nature, but it is not typically associated with death or permanent disability in the immediate sense. However, "Class II" does not mean the risk is negligible. It signals that the manufacturing process failed to meet current Good Manufacturing Practice standards, which are designed to ensure every pill is exactly what it claims to be. Therefore, the individuals most at risk are those who trust this medication for daily physiological regulation and cannot afford any uncertainty in its purity or potency.
- Primary Group: Adults prescribed Cinacalcet Hydrochloride 90 mg tablets manufactured by Cipla Ltd., specifically lot 5PB0563.
- Vulnerable Subgroups: Patients with chronic kidney disease, older adults with multiple comorbidities, and individuals managing complex metabolic disorders.
- Risk Type: Long-term exposure to potential carcinogenic impurities (N-nitroso-cinacalcet) rather than immediate acute toxicity.
How to tell if you have the recalled item
Identifying whether your medication is part of this specific recall requires a careful and methodical inspection of your prescription bottle. Because this issue involves Cipla USA, Inc. and its manufacturing partner, Cipla Ltd., the details on your label are your primary source of truth. Do not rely solely on the name of the drug, as "Cinacalcet Hydrochloride" is a generic medication that may be manufactured by various companies. You must verify several specific data points printed directly on the packaging to confirm if your batch is affected.
First, locate the National Drug Code (NDC) number on the bottle label. For this recall, the affected product carries the NDC 69097-412-02. This unique identifier links the specific manufacturer, trade name, and package size to federal databases. If your bottle does not display this exact NDC sequence, it is likely not part of this specific recall action, though you should always double-check with your pharmacist if you are uncertain.
Next, examine the lot number and expiration date, which are critical for pinpointing the exact batch in question. The recall specifically targets bottles with Lot Number 5PB0563. You will typically find this alphanumeric code printed on the side or back of the bottle, often near the barcode or alongside the expiration information. In this case, the associated expiration date is April 30, 2027 (Exp 4/30/2027). If your bottle has a different lot number, even if it shares the same expiration date, it is not included in this recall. Conversely, if you have a different NDC but the same lot number, you should still verify with the manufacturer or FDA resources, as distribution patterns can sometimes overlap.
Please also note the physical characteristics of the product to ensure accuracy. The recalled item consists of Cinacalcet Hydrochloride Tablets in a 90 mg strength. These tablets are packaged in a 30-count bottle. If you have a different count, such as a 60-count or 100-count package, or a different dosage strength, this specific recall notice does not apply to your container. The product is marked as "Rx Only," indicating it is a prescription medication manufactured for Cipla USA, Inc., located at 10 Independence Boulevard, Suite 300, Warren, NJ 07059, and manufactured by Cipla Ltd. in Patalganga, India.
To be absolutely certain, take your bottle to your local pharmacy or contact the manufacturer directly using the information provided on the label. Pharmacists have access to real-time recall databases and can quickly cross-reference your NDC and lot number against the FDA’s official recall list. Do not discard your medication immediately upon suspicion; verification is the safest first step. If you are unsure about the origin of your prescription, your pharmacist can also confirm whether it was distributed nationwide through their standard supply chains, as this recall covers distribution patterns across the entire United States.
What to do — step by step
When a medication recall occurs, especially one involving potential chemical contamination like the current situation with Cipla USA, Inc., feeling unsure of your next move is completely normal. The most important thing to remember is that you are not alone in this process, and there is a clear, logical path to ensure your safety and resolve the issue. Because the official remedy for this specific recall involving Cinacalcet Hydrochloride Tablets has not been explicitly stated in the current FDA notice, you must take proactive steps to protect yourself and stay informed. Do not wait for instructions to arrive in the mail; instead, follow these concrete steps immediately.
- Stop taking the medication right away. Even if you feel perfectly healthy and are managing your condition well, do not consume any more of this specific batch. The hazard involves N-nitroso-cinacalcet, a substance that exceeds acceptable daily intake limits due to cGMP (current Good Manufacturing Practice) deviations. While the long-term effects of such exposure are complex, avoiding further intake is the only way to eliminate risk entirely. If you have already taken the pills and are concerned about health impacts, contact your healthcare provider promptly for personalized advice.
- Verify your bottle against the recall details. Pull your medication bottle from your cabinet and carefully examine the label. You are looking for a precise match on three key identifiers: the NDC number 69097-412-02, the lot number 5PB0563, and the expiration date of 4/30/2027. The product is a 90 mg, 30-count bottle of Cinacalcet Hydrochloride Tablets manufactured by Cipla Ltd. in India and distributed by Cipla USA, Inc. If your bottle matches these details exactly, it is part of the Class II recall. If the lot number or NDC does not match, your medication is likely safe to continue using as prescribed.
- Contact your pharmacist or prescribing doctor. Since the official remedy (such as a refund or replacement protocol) is not yet stated in the public notice, your healthcare team is your best resource. Call your pharmacist first; they can verify the lot numbers in their system and may have received internal communications from Cipla USA, Inc. regarding how to handle returns or substitutions. Then, inform your doctor so they can adjust your prescription if necessary. Do not stop taking prescribed medication long-term without medical guidance, but do pause use of the recalled product immediately.
- Save the bottle and wait for further instructions. Keep the recalled bottle in a safe place where you will not accidentally use it again. Since the distribution pattern is nationwide and the remedy is not yet specified, Cipla USA, Inc. or the FDA may issue updated guidance on how to return the product for a refund or replacement. Check the FDA website regularly for updates on this specific recall. If you have questions about the manufacturing process or the nature of the cGMP deviations, you can also contact Cipla USA, Inc. directly at their Warren, NJ address listed in the recall notice.
Remember, a Class II recall indicates that use of the product could cause temporary or medically reversible health problems. By following these steps, you are taking control of your health and ensuring that you remain safe while the manufacturer resolves the issue. Stay calm, stay informed, and keep your healthcare providers in the loop.
Your refund, repair, or replacement options
When a medication is recalled due to manufacturing deviations, the most immediate concern for consumers is often financial: how do they get their money back or receive a safe alternative? In this specific case involving Cipla USA, Inc. and its Cinacalcet Hydrochloride Tablets, the official recall documentation filed with the FDA does not explicitly state the remedy. This means the standard procedures for refunds, replacements, or repairs are not clearly defined in the public record we have access to. While it is common for pharmaceutical recalls to involve automatic refunds through pharmacies or direct mail-in reimbursement forms from the manufacturer, those details are simply not listed here. Therefore, you cannot assume a specific process exists based solely on this report.
Because the remedy is unstated, your first and most critical step must be proactive communication. You should contact the pharmacy where you originally purchased the medication immediately. Pharmacies are required to maintain detailed records of their inventory and supplier information. They can confirm if they received the affected lot (Lot # 5PB0563) and will typically guide you through their internal return process. In many cases, pharmacies will issue a full refund or provide a substitute product from a different manufacturer without requiring you to mail anything back, especially for Class II recalls where the health hazard is serious but not life-threatening.
If your pharmacy cannot resolve the issue directly, you must reach out to Cipla USA, Inc. directly. Although the recall notice does not provide a specific customer service phone number or email address for this particular incident, it does list the manufacturer’s physical address: 10 Independence Boulevard, Suite 300, Warren, NJ 07059. You should call their main corporate line and ask to be connected to the Pharmacovigilance or Quality Assurance department regarding the Cinacalcet Hydrochloride recall. When you speak with them, have your prescription bottle, the NDC number (69097-412-02), and the lot number ready.
It is important to understand why the remedy details might be missing from this initial report. Sometimes, remediation plans are communicated privately to healthcare providers and pharmacies before being fully detailed in public summaries. However, you should not wait for a letter in the mail. Do not attempt to keep the medication because it has not expired (the expiration date is April 30, 2027). The hazard here is chemical contamination with N-nitroso-cinacalcet, which exceeds acceptable daily intake levels, regardless of how fresh the pills are. Your financial recovery is secondary to your health safety; therefore, prioritize getting a safe alternative from your doctor or pharmacist before worrying about the refund process. Document all interactions, including dates and names of representatives you speak with, in case follow-up is needed later.
What can happen if you ignore it
When you see a recall notice from the Food and Drug Administration (FDA) regarding a medication like Cinacalcet Hydrochloride, it is natural to feel frustrated by the inconvenience of returning a prescription. However, ignoring this specific alert carries risks that go far beyond simple logistical hassle. The core issue here involves cGMP (current Good Manufacturing Practice) deviations resulting in the presence of N-nitroso-cinacalcet above the acceptable daily intake (ADI). To understand why continuing to use this medication is dangerous, we must look at what N-nitroso compounds actually are and how they interact with the human body over time.
N-nitroso compounds, including N-nitroso-cinacalcet, are classified as potential carcinogens. This means that exposure to these substances has been shown in scientific studies to cause cancer in animal models. The FDA sets an "acceptable daily intake" limit for such impurities based on rigorous toxicological data. This limit represents the amount of the substance a person can ingest every day for a lifetime without a significantly increased risk of developing cancer. When the concentration of N-nitroso-cinacalcet exceeds this ADI, the safety margin that protects your long-term health is compromised.
The danger here is not typically acute or immediate in the way that a sudden allergic reaction might be. You will not feel "poisoned" after taking one extra dose. Instead, the risk is cumulative and statistical. By continuing to take this medication, you are exposing your body to higher levels of a known carcinogenic impurity than regulatory agencies have deemed safe. While the FDA has not reported any specific incidents or injuries in this recall notice, the decision to issue a Class II recall indicates that the product could cause temporary health problems or pose a slight threat of serious nature. In the context of carcinogens, "serious" refers to the long-term potential for cellular damage that can lead to malignancies years down the line.
Cinacalcet is used to treat conditions related to calcium levels in the blood, often in patients with secondary hyperparathyroidism or parathyroid carcinoma. These patients are typically on long-term therapy. For someone managing a chronic condition, the temptation to keep taking medication until a new bottle arrives is strong. However, the integrity of the drug's manufacturing process has been called into question. The presence of this impurity suggests that the quality control measures at the manufacturing facility failed to filter out or prevent the formation of these nitroso compounds. Continuing to use the product means trusting a broken process.
Ignoring the recall also denies you the opportunity to switch to a safer alternative or to consult your healthcare provider about any necessary adjustments to your treatment plan. While Cinacalcet itself is an effective drug for its intended purpose, the specific batches involved in this recall (Lot #5PB0563) are contaminated. The consequence of inaction is that you remain exposed to unnecessary carcinogenic risk without gaining any therapeutic benefit that isn't already available through other, safe sources of medication. In regulatory terms, a Class II recall often involves products that might cause adverse health consequences where the probability of serious adverse health consequences is remote. However, "remote" is not "zero," and when it comes to cancer risk, there is no acceptable level of exposure above the established safety limits for impurities.
Therefore, the real-world consequence of ignoring this recall is the voluntary acceptance of a heightened long-term health risk. It is a gamble with your future well-being for the sake of short-term convenience. The FDA’s role is to ensure that every pill you take meets strict safety standards. When that standard is breached, the only responsible path is to remove the product from your routine immediately and replace it with a verified safe alternative under medical supervision.
Staying safe: broader tips
When it comes to prescription medications like cinacalcet hydrochloride, your safety net extends far beyond the moment a recall is announced. While specific alerts are vital for immediate action, building a long-term habit of pharmaceutical vigilance is what truly protects your health over time. The most effective strategy begins with how you store and manage your prescriptions at home. Medications are sensitive to their environment; heat, humidity, and light can degrade active ingredients or alter chemical stability long before an expiration date arrives. Keep your bottles in a cool, dry place away from bathroom sinks and kitchen windows. For certain medications, this might mean using a locked cabinet rather than the open counter, ensuring that temperature fluctuations do not compromise the integrity of the pills inside.
Another critical layer of defense is maintaining an updated medication inventory. Many people fill prescriptions and simply forget what they have until they need it again, which can lead to accidental double-dosing or using outdated supplies. Take a few minutes each month to review your medicine cabinet. Check expiration dates not just on the surface, but on every bottle, including over-the-counter supplements that may interact with your prescription drugs. This practice also helps you identify if you have any products from manufacturers known for past quality issues, allowing you to proactively consult your pharmacist about potential alternatives before a problem arises.
Staying informed requires setting up reliable channels for news, rather than waiting for a letter to arrive in the mail. Subscribe to email alerts from the FDA’s Office of Drug Safety and the Center for Drug Evaluation and Research. These agencies provide timely updates on Class I, II, and III recalls, along with detailed information on why a product was pulled and who is affected. Additionally, consider using reputable third-party medication tracking apps that allow you to input your specific prescriptions; these tools can send push notifications if your specific lot numbers are flagged in a recall database. This proactive approach ensures you are never caught off guard by sudden supply chain disruptions or quality control failures.
Finally, never hesitate to question the source of your medication. Always verify that you are picking up your prescription from a licensed pharmacy and that the packaging appears intact and professional. If a bottle looks tampered with, discolored, or smells unusual compared to your previous fills, do not take the medication. Report these concerns immediately to your pharmacist and the manufacturer’s customer service line. Your attention to detail acts as the final checkpoint in a complex safety system, ensuring that you receive only the high-quality care your health deserves.